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inhibited the phosphorylation of p38 and JNK kinases along with its
enhancing effect on MKP-1 expression; and when MKP-1 was down-
regulated by siRNA, aurothiomalate’s ability to inhibit p38 and JNK
phosphorylation, and COX-2 expression reduced signiﬁcantly.
Conclusions: The results provide a novel mechanism for the anti-
inﬂammatory action of aurothiomalate through increased MKP-1 expres-
sion and reduced p38 and JNK MAP-kinase activation, and COX-2
expression. The results propose MKP-1 as a promising novel target for
the development of disease modifying drugs for RA and OA.
*Murine H4 chondrocyte cell line was kindly provided by Peter van der
Kraan, Laboratory of Experimental Rheumatology, University Medical
Center Nijmegen, Netherlands.
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Purpose: Aggrecan, the main proteoglycan of articular cartilage, is
composed of a core protein containing 3 globular domains G1, G2 and
G3. The interglobular domain between G1 and G2 is the primary site for
enzyme attacks of the molecule, matrix metalloproteinases (MMPs) and
aggrecanases, generating fragments with speciﬁc N-terminal ends. The
aim of this study was to identify aggrecan fragments circulating in hu-
man serum/plasma with speciﬁc antibodies corresponding to neoepitope
generated by aggrecanases.
Methods: Pools of serum from controls (n = 22; mean age: 62 yrs ±2.7)
and patients suffering from osteoarthritis (n = 19; mean age: 64±4) and
plasma from patients suffering from RA (n= 20; 10 men and 10 women,
mean age: 61.7 yrs ±3.9, DAS> 4.8) were investigated with afﬁnity
puriﬁcation and Western blots using two monoclonal antibodies. First,
monoclonal antibody BC-3 recognizing a neoepitope generated by aggre-
canases in position 374-ARGSV. Secondly, a monoclonal antibody F-78
was used recognizing a repetitive epitope exposed at least twice on G1
and G2 domains.
Results: In Western blot, BC-3 recognized a band migrating at 45 kDa in
RA patients only. The strong reactivity was abolished by pre-incubation
with the peptide corresponding to BC-3 epitope. To further investigate the
distribution of ARGSV-carrying neoepitopes in RA plasma, we subjected
the plasma to afﬁnity puriﬁcation using either BC-3 or F-78. Again, the
major reactivity was conﬁned to a 45 kDa band using either BC-3 or F-78
as detecting antibody in western blots of the eluted material.
Conclusions: We have identiﬁed an aggrecan fragment of MW 45 kDa
generated by aggrecanase cleavage with a N-terminal neoepitope 374-
ARGSV and containing G2 domain suggesting that this fragment is a
good candidate marker for a sandwich assay using monoclonal antibodies
BC-3 and F-78. Apparently, this fragment of aggrecan is primarily found
in circulation of RA patients and additional investigations are underway
to determine the molecular nature of this fragment.
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Purpose: One hallmark of the progression of osteoarthritis and rheuma-
toid arthritis is the gradual destruction of articular cartilage in affected
joints, in part mediated the matrix metalloproteases (MMPs) and aggre-
canases. Collagen type II is found almost exclusively in cartilage tissue
where it constitutes over 60% of the dry weight. Degradation of collagen
type II is for the major part mediated by MMPs. Because of the abundance
of collagen type II in cartilage and its tissue speciﬁcity, MMP generated
fragments of type II collagen (neo-epitopes) are highly interesting as
cartilage degradation markers. The aim of this study was to develop
new biochemical enzyme immuno assays (EIA) of MMP cleaved collagen
type II fragments to be used as markers of cartilage degradation.
Methods: Two neoepitopic sites representing ubiquitous MMP-generated
fragments of collagen type II identiﬁed from cleavage of collagen type II
were selected. The two neoepitopes corresponded to cleavage between
amino acids 845–846 (neoepitope I) and 872–873 (neoepitope II).
Peptides reﬂecting the neoepitopic sites (846LTGPAG and RDGAAG872)
were synthesized and used for immunization of balb/C mice and rabbits.
Competitive EIA assays were established using biotinylated synthetic
peptide as coater and the immune sera as primary antibody. The assays
were used to proﬁle the proteolytic events in the well characterized ex vivo
articular cartilage explant model. The cartilage explants included catabol-
ically stimulated TNFa (tumor necrosis factor alpha) and oncostatin M
cultures, non-stimulated cultures, and metabolically inactive cultures.
Results: In catabolically stimulated bovine cartilage explant cultures a
low concentration of neoepitope I of below 50ng/ml was found in samples
collected day 3, 6, and day 11. However after prolonged catabolic stim-
ulation of 22 days a more than 20-fold dramatic increase was observed
reaching a level higher than 1000 ng/ml. In comparison the control culture
of non-stimulated explant culture media had the same low level below
50ng/ml on day 3, 6, and 11, and reached only 100 ng/ml at day 22.
The metabolically inactive culture remained below 50ng/ml during the
complete culture period. A similar pattern of a dramatic increase in the
22-day catabolically stimulated culture was observed in human articular
cartilage explant cultures. The pattern of other marker of neopitope II
mirrored that of neoepitope I.
Conclusions: Two new immunoassays of neoepitope markers of collagen
type II degradation were established. Measurement of these neoepitopes
in both the bovine and human ex vivo articular cartilage explant model
demonstrated that the two markers reﬂect late cartilage degradation.
Further studies are needed to investigate whether these fragments are
of clinical relevance.
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Purpose: The objective of the present study was to investigate the
changes of serum level of cartilage oligomeric matrix protein (COMP)
during a 30-min exercise after 12-weeks of regular impact or non-impact
exercise.
Methods: Blood samples were drawn from 33 healthy sedanter males
immediately before and after and 0.5 h after a 30-min walking exercise
on a motor-driven treadmill at 5 km/h speed. Serum COMP concentra-
tions were determined using a commercial enzyme-linked immunosorbent
assay (AnaMar Medical, Go¨teborg, Sweden). After ﬁrst measurements
participants were randomly and equally assigned to impact group (run-
ning, n = 11) non-impact group (swimming, n = 11), and control conditions
(n = 11). All exercise groups participated in sessions of 40 minutes per
day, 3 days per week for 12 weeks. Each session started with a 5min.
of warm-up, continuing with main set for 30min. at their individual target
heart rate zone which was determined according to the ACSMs’ guide-
lines (60−70% of heart rate reserve) and lasted with a 5min. cool down
period. The target heart rate reserve (HRR) was determined by Karvo-
nen formula (Bompa, 1994). Participants in running and cycling groups
partake sessions in the human performance laboratory one by one, three
times a week throughout their weekly Schedule (throughout Mondays,
Wednesdays and Fridays) which was determined by the instructor while
swimming group perform exercise sessions in indoor swimming pool. The
heart rate of the subjects was monitored with Heart rate monitors (Polar
Vantage NV Heart Rate Monitor) during exercise sessions. Throughout
the 12-week period, the control group was told not to participate in any
organized or structured exercise and continue their daily life activities.
At the end of the 12-weeks intervention period, post tests were applied
with the same procedure of pre-tests. The experimental protocol was
approved by local ethics committee. All subjects signed a consent form
after being fully informed of the study’s methods, possible side effects and
the purpose. Serum COMP concentrations within the groups of running,
swimming and control were compared using separate repeated measures
of analysis of variance (repeated-ANOVA). Main effect was compared
for multiple comparisons by Bonferroni conﬁdence interval adjustment.
Statistical computation was performed using the SPSS. The level of
statistical signiﬁcance was accepted as p< 0.05.
Results: In the pre-tests measurements, signiﬁcant change between the
serum COMP concentrations were found only at P< 0.1 level. Immediately
after the walking exercise, serum COMP concentrations were increased
signiﬁcantly in running (P=0.084) and control groups (P=0.064). In the
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post-tests, changes were observed only at exercise groups. In running
group, signiﬁcant increase (P=0.049) occurred immediately after the
walking exercise. Also in swimming group COMP serum concentration
increased signiﬁcantly (P = 0.084) immediately after the walking exercise.
Signiﬁcant decrease (P=0.051) of serum COMP concentration were
observed at direct impact running group at 30-minutes recovery after
walking exercise.
Conclusions: In this age group, moderate walking activity can have
little inﬂuence on the increase serum COMP concentrations. However,
signiﬁcant decrease of serum COMP concentration after walking exercise
observed only in running group. This change, after 12-weeks regular
weight-bearing impact exercise, will be explained with the functional
adaptation of articular cartilage to speciﬁc environmental requirements.
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Purpose: Calcium phosphate crystals such as basic calcium phosphate
(BCP) and calcium pyrophosphate dihydrate (CPPD) are known to occur
in intra-articular synovial ﬂuid (SF) and may be associated with a number
of destructive arthropathies. For instance, BCP crystals are found in up to
70% of osteoarthritic joints and current data suggests that BCP crystals
represent a potential therapeutic target. Previous studies have used
enzymatic and chemical methods to reduce organic contamination in the
biological sample in an attempt to facilitate crystal detection. However, by
doing so, valuable information from other biomarkers in SF sample will
be lost. Bisphosphonates are commonly used as pharmaceutical drugs
for the treatment of osteoporosis and are known to bind very speciﬁcally
and strongly to the surface of calcium phosphate. We have exploited this
chemical speciﬁcity to create an extraction platform which can isolate
calcium phosphate crystals from SF samples in a simple and selective
manner.
Methods: Spiked samples were prepared by suspending synthetic cal-
cium phosphate crystals (HA/CPPD) in artiﬁcial SF (3% hyaluronan in
human serum) at concentrations normally found in vivo. SF samples
were aspirated from the affected joints (mainly knees and shoulders)
of patients with OA and/or other arthropathies. Commercially available
superparamagnetic beads (Dynal) were derivatised with bisphosphonates
(neridronate) using carbodiimide coupling chemistry. Bisphosphonate-
modiﬁed superparamagnetic beads (BPSM beads) were mixed and incu-
bated with the SF samples for one hour. Removal of unwanted biological
material and washing was achieved by using a small permanent magnet
to pull the beads to the side of the vessel. Scanning electron microscopy
(SEM) and energy dispersive x-ray (EDX) spectroscopy (Hitachi SN-3000)
was used to conﬁrm the presence/absence of crystals captured by the
beads. Calcium content was measured using an o-cresolpthalein com-
plexone assay on a Biotek Powerwave XS 96-well reader. Raman spectra
were collected on a Renishaw InVia Raman microscope (514/785 nm
laser excitation).
Results: SEM/EDX measurements of spiked SF showed that HA/CPPD
crystals were successfully isolated by the BPSM beads. Typically, high
levels of calcium measured using colorimetry were consistent with the
presence of crystals in the sample as found in SEM. Raman spectral
features indicated that there are certain marker bands that are speciﬁc
to the type of crystal species present, such as the speciﬁc signature
modes at 960 cm−1 (BCP) and 1043 cm−1 (CPPD). Hence, Raman mi-
crospectroscopy provides a means of detecting the type of crystal present
following the initial separation step.
Conclusions: In this approach, the surface of superparamagnetic poly-
mer beads was modiﬁed with commercially available bisphosphonates,
essentially providing the beads with the capability to capture calcium
phosphate crystals from SF samples. Once isolated, the crystals were
successfully detected and characterised using colorimetry, scanning elec-
tron microscopy and Raman microspectroscopy. The main challenge is
to correlate the high levels of calcium with the presence of crystals and
the proposed diagnosis. This aspect will require the analysis of a larger
pool of samples and may provide a tool for improved diagnosis and
characterisation of OA and other crystal related pathologies.
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Purpose: Synovial ﬂuid examination is a valuable but under-utilised diag-
nostic tool for arthritis. The link between basic calcium phosphate (BCP)
crystals in synovial ﬂuid (SF) and osteoarthritis (OA) is well described.
BCP crystals are unique OA and may serve as a biomarker and aid to
more accurate diagnosis of the disease. The detection and quantiﬁcation
of BCP crystals in OA is particularly difﬁcult due to their submicron
dimensions and the challenges of ﬁnding them within the complex and
viscous synovial ﬂuid matrix. A further complication resides in the ability
to distinguish them from the other calcium-containing crystals that can co-
exist in synovial ﬂuid such as calcium pyrophosphate dihydrate (CPPD),
commonly associated with pseudogout. The aim of our work is to develop
semi-quantitative, colorimetric assays for detecting calcium phosphate
crystals in SF.
Methods: Model SF samples were prepared by suspending synthetic
hydroxyapatite (HA) and CPPD crystals in simulated SF (3% hyaluronan
in human serum) at concentrations normally found in vivo. Patient SF
samples were aspirated from the affected joints (mainly knees and
shoulders) of 20 people with OA and/or other arthropathies. For crystal
extraction, SF samples (100ml) were ﬁrst treated with sodium hypochlorite
and ultrasonicated to break down the organic matrix. Samples were then
centrifuged to pellet the crystals. This was followed by a number of
washing steps with water. The pellet was dissolved in 1N nitric acid to
dissociate the crystals into their constituent ions. Calcium concentration
was measured using an o-cresolpthalein complexone assay (1−10mg/l
range). Phosphate concentration was measured using a modiﬁed molyb-
date blue method (1−50mg/l) on a Biotek Powerwave XS 96-well reader
and also determined using a vanadate-molybdate reagent with 0.002M
solution of malachite green (MG) as a chromophore. Values obtained
for the samples were normalised against analytical grade calcium and
phosphate standards. Scanning electron microscopy (SEM) and energy
dispersive x-ray (EDX) spectroscopy (Hitachi SN-3000) were used to
conﬁrm the presence/absence of crystals isolated within the pellet.
Results: Sodium hypochlorite solution was found to be an effective
deproteinising agent that helps to degrade the organic material but
does not break down HA and CPPD crystals due to their stability in
basic solution. SEM of spiked SF showed that HA/CPPD crystals were
successfully isolated from the organic matrix with no signs of degradation.
Calcium levels found in patient SF samples ranged from 40–200 (mg/l).
The presence of BCP or CPPD could be diagnosed using the Ca:P ratio.
The ratio closer to 1:1 indicated excess of CPPD and closer to 1:1 –
excess of HA crystals. Typically, high levels of calcium and phosphate
levels were consistent with the presence of crystals in the sample as
found in SEM.
Conclusions: We present a simple, semi-quantitative method for detect-
ing calcium phosphate crystals in SF. The main challenge is to correlate
the high levels of calcium/phosphate with the presence of crystals and
the proposed diagnosis. This aspect will require the analysis of a larger
pool of samples and may provide a tool for improved diagnosis and char-
acterisation of OA and other crystal related pathologies. The MG method
is suitable for naked-eye categorising of SF samples for high/medium/low
phosphates content.
